Monte Rosa Therapeutics, Inc. (GLUE) is currently Overvalued by 9.91%

Monte Rosa Therapeutics, Inc. (GLUE) appears overvalued by approximately 9.91% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Downside (live) 9.91% (from live valuation API)
Confidence (live) 4/10 (Low conviction overvalued)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$24.40

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is Monte Rosa Therapeutics, Inc. overvalued or undervalued?

For Monte Rosa Therapeutics, Inc., intrinsic value ties fair value to sustainable cash generation; with the stock above that level, the snapshot reads as a premium versus fundamentals rather than a pure sentiment call.

Historical valuation for GLUE shows cycles where multiples expanded and compressed; today’s positioning rhymes more with growth optimism than the mid-range of its recent history.

Market expectations boil down to growth, risk, and return on capital—current levels bake in strong execution, so disappointments hit harder. Cross-check with live ratios when your API is connected.

Key metrics

P/E ratio: 19.2x
Revenue growth (TTM y/y): 8%
Profit margin: 10.5%
Fair value (model): Unlock

Next steps

Frequently asked questions — GLUE

Is GLUE overvalued right now?

Based on our 2026 models, Monte Rosa Therapeutics, Inc. (GLUE) appears overvalued at $24.40 with roughly 9.9% downside versus fair value. Confirm with valuation ratios and financials before acting.

What is Monte Rosa Therapeutics, Inc.'s intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether GLUE trades above or below fair value. At $24.40, Monte Rosa Therapeutics, Inc. currently looks overvalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is Monte Rosa Therapeutics, Inc.'s intrinsic value calculated?

Tickerplace calculates GLUE's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is GLUE undervalued right now?

A stock is undervalued when price sits below a supportable fair value range. Check whether GLUE's gap aligns with fundamentals using the ratios and financial links on this page.

Peers for GLUE: open their overvalued / undervalued view.

Instant valuation answer